Weight-loss drug developer BioAge raises $198 million in U.S. IPO
BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the range at $18 per share, the weight-loss drug developer said on Wednesday. The surging popularity of weight-loss drugs,
IPO, MNTN and Ryan Reynolds
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United ...
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...
Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Read more here.
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback